64,287 Shares in Tempus AI, Inc. $TEM Purchased by Fagan Associates Inc.

Key Points

• Fagan Associates acquired 64,287 Tempus AI shares in the third quarter, valued at approximately $5.27 million. Institutional investors collectively own 24.22% of the company.
• Tempus AI reported quarterly revenue of $382.5 million, up 21.6% year over year, and an adjusted loss of $0.04 per share that beat analyst expectations. Analysts expect the company to remain unprofitable for the full fiscal year.
• Tempus AI shares recently traded at $68.22, while analysts’ consensus rating is Hold with an average price target of $71.84. Insiders sold 1.28 million shares worth approximately $80.4 million over the past three months.

Fagan Associates Inc. bought a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 64,287 shares of the company's stock, valued at approximately $5,265,000.

Several other institutional investors have also recently bought and sold shares of TEM. Arkadios Wealth Advisors boosted its position in Tempus AI by 9.6% during the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company's stock worth $224,000 after acquiring an additional 435 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Tempus AI by 54.3% in the third quarter. GAMMA Investing LLC now owns 1,239 shares of the company's stock valued at $101,000 after purchasing an additional 436 shares during the last quarter. EMC Capital Management acquired a new stake in shares of Tempus AI in the second quarter valued at approximately $29,000. NewEdge Advisors LLC lifted its position in shares of Tempus AI by 1.3% in the first quarter. NewEdge Advisors LLC now owns 42,996 shares of the company's stock worth $1,944,000 after purchasing an additional 536 shares in the last quarter. Finally, SteelPeak Wealth LLC lifted its position in shares of Tempus AI by 6.2% in the first quarter. SteelPeak Wealth LLC now owns 9,245 shares of the company's stock worth $418,000 after purchasing an additional 538 shares in the last quarter. Institutional investors own 24.22% of the company's stock.

Insiders Place Their Bets

In other Tempus AI news, CEO Eric P. Lefkofsky sold 250,000 shares of the business's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the transaction, the chief executive officer owned 100,000 shares of the company's stock, valued at $7,747,000. The trade was a 71.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nadja West sold 3,000 shares of the company's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $69.00, for a total value of $207,000.00. Following the completion of the sale, the director owned 31,981 shares in the company, valued at $2,206,689. This represents a 8.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,280,965 shares of company stock worth $80,397,564 in the last three months. Insiders own 24.26% of the company's stock.

Tempus AI Stock Performance

NASDAQ TEM traded up $0.23 on Tuesday, hitting $68.22. 4,144,923 shares of the stock were exchanged, compared to its average volume of 6,223,961. The company has a market capitalization of $12.31 billion, a PE ratio of -47.37 and a beta of 3.54. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The business's fifty day moving average is $66.46 and its 200 day moving average is $55.91. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $97.25.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company's quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.22) EPS. Research analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEM has been the subject of several recent research reports. HC Wainwright increased their target price on shares of Tempus AI from $56.00 to $66.00 and gave the stock a "buy" rating in a report on Friday, September 11th. Weiss Ratings lowered shares of Tempus AI from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday, September 28th. Rothschild & Co Redburn began coverage on shares of Tempus AI in a research note on Tuesday, September 8th. They issued a "neutral" rating and a $67.00 price target on the stock. Stifel Nicolaus cut their price target on shares of Tempus AI from $60.00 to $50.00 and set a "hold" rating on the stock in a research report on Monday, August 3rd. Finally, Freedom Capital raised shares of Tempus AI to a "hold" rating in a research report on Tuesday, June 30th. Eleven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $71.84.

Tempus AI Company Profile

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.